Mar
01
2003

Hyperthermic Chemotherapy For Colon Cancer

When colon cancer comes back (Duke stage D cancer) there often are seedlings of cancer cells in the peritoneal cavity, which in the past made surgery impossible. However, at Montreal’s Maisonneuve-Rosemont Hospital the surgical oncologist, Dr. Pierre Dubé, is using a brand new technique that allows to do surgery even in these difficult cases. It has been known for some time that cancer cells are heat sensitive.

At the time of the surgery all of the visible cancer is removed, like with ovarian cancer, using a cytoreductive surgery approach. At the end all invisible cancer cells are treated with a combination chemotherapy fluid that is introduced into the abdominal cavity and that is heated in a controlled manner. Heat probes measure the temperature and make sure the fluid is heated to 44°C (111°F). Other experiments have shown that at this temperature chemotherapeutic agents enter into the cancer cells faster, as they had been rendered more fragile by the heat. The end result is an increase in survival by 2 to 2 1/2 years. This is a breakthrough because in the past conventional combination chemotherapy for this group of advanced colorectal cancer patients achieved a remission (meaning “response rate”) of 0%. Now with this new technique there is a remission rate of 30% to 50%. Hyperthermic chemotherapy for colon cancer was pioneered at the Gustave Roussy Institute in Paris where Dr.Dubé was introduced to this technique. This was reported in the Jan. 14, 2003 edition of The Medical Post (page 7). According to Dr.Dubé about 10% of all colorectal cancer patients will need this type of surgical approach and about up to 25% of patients who develop cancer spread into the abdominal cavity (peritoneal carcinomatosis) would be potential candidates for this treatment modality.

Hyperthermic Chemotherapy For Colon Cancer

Hyperthermic Chemotherapy For Colon Cancer

Comments: Recently there has been a paper intitled “Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis” by P.Shen et al. (Arch Surg – 01-JAN-2003; 138(1): 26-33). 109 patients with carcinomatosis of the abdominal cavity with different cancers were treated with cytoreductive surgery and hyperthermic chemotherapeutic solutions. With this procedure, after complete removal of gross cancerous disease, the 3-year survival rate achieved 68% versus 21% of those where gross cancer removal was not entirely possible.

Last edited October 25, 2014

Jan
31
2003

February Readers’ Digest Edition… Poisons Used For Healing

In this February’s Readers’ Digest edition there is an article about the use of poisons of nature for healing purposes (article entitled “Healing Power of Poison”). For instance arsenic trioxide has been used recently in a trial with leukemia patients to get a remission of leukemia in 70% of cases. Arsenic, which normally is a powerful poison, has in the right dilution this healing effect in leukemia with less toxic side-effects than chemotherapy.

Dr. J. Michael McIntosh, a psychiatrist at the University of Utah, is researching the poisonous effect of a marine snail that attaches to and kills fish with a toxin. This poison is a powerful painkiller. It is several hundred times stronger than morphine, but is useful as it does not have any effect on the strength or functioning of muscles. This substance used in the right diluted dose, may one day be used for the treatment of chronic pain syndromes.

The bacterium Clostridium botulinum produced a powerful toxin, which causes botulism. Neurologists and plastic surgeons are using this poison in a diluted form as “Botox” to inject into wrinkles of skin to make your face look younger. It is also used for chronic spastic muscle conditions like cerebral palsy or tardive dyskinesia.

February Readers' Digest Edition... Poisons Used For Healing

February Readers’ Digest Edition… Poisons Used For Healing

Newer reference regarding the use of arsenic trioxide: http://bloodjournal.hematologylibrary.org/content/107/7/2627.abstract

Last edited December 10, 2012

Nov
01
2002

New Blood Test To Predict Breast Cancer Survival Rate

Dr. Keyomarsi, a researcher and radiation oncologist from the M.D. Anderson Cancer Institute in Houston/Texas, has published a very important piece of research in the New England Journal of Medicine (N Engl J Med 2002;347:1546-1547,1566-1575). A group of 394 breast cancer patients were followed for 6.4 years and cyclin E was measured with a special blood test. Cyclin E is a key substance involved in cell division in general and also in breast cancer cells. Dr. Kyomarsi’s research showed that cyclin E, and in particular high levels of its socalled “truncated isoforms”, correlated very well with poor survival. On the other hand low cyclin E levels (truncated isoforms) were a powerful predictor for excellent survival. In the above mentioned breast cancer study 12 patients out of a group of stage 1 patients (= localized breast cancer) died after an average of 4.1 years from the point of diagnosis. All of these patients had high cyclin E levels. In contrast, none of the other stage 1 patients had died within 5 years from the diagnosis and all of their cyclin E levels were low. Other known risk factors for poor survival are lymph gland metastases, negative estrogen receptors on the surface of the cancer cells and late-stage disease. Each of those factors has a risk of about 1.7-fold. A high (truncated isoform) cyclin E level is associated with a 2.1-fold risk when compared to the low risk group with a low cyclin E level. There is a subgroup of breast cancer patients with high total cyclin E levels who have a risk of 13.3-fold of dying from breast cancer.

New Blood Test To Predict Breast Cancer Survival Rate

New Blood Test To Predict Breast Cancer Survival Rate

You may want to read these useful related links to chapters of my free Internet based Nethealthbook: A general overview regarding cancer: http://www.nethealthbook.com/articles/cancer_canceroverview.php#cancer This chapter deals specifically with breast cancer: http://www.nethealthbook.com/articles/cancer_breastcancer.php

Last edited December 10, 2012

Oct
01
2002

Smog From City Roads Reduces Your Life Expectancy 2-Fold

Our ancestors already knew the benefits of fresh air and the fact that your grandmother likely knew: country living is healthier than city living. Let me qualify this somewhat: A recent study from the Netherlands showed that smog in cities has a detrimental effect on a person’s health (based on Lancet 2002;360:p.1203-1209). Dr. Gerard Hoek and his team from the Utrecht University revisited a group of about 5000 patients 15 years after the completion of a lung cancer study that was done in 1986 on these patients.

The authors looked up the addresses and classified two groups based on where these patients lived in 1986, either beside a busy congested road in the city or in a rural country area. 11% of the patient population had died of lung or heart disease during this period of time. When all of the other factors were kept constant and only the area where they lived was different, these authors found a significant 2-fold difference, which was attributed to chronic exposure to air pollution from traffic. The main reasons for this difference, they stated, was due to chronic exposure to black smoke and nitrogen dioxide from the exhaust fumes of cars. This study showed that air pollution by itself can double the death rate over a longer time period such as 15 years. In other words: It matters what you breathe! Useful related links to chapters of my free Internet based Nethealthbook:

Smog From City Roads Reduces Your Life Expectancy 2-Fold

Smog From City Roads Reduces Your Life Expectancy 2-Fold

Cardiovascular Disease:
http://www.nethealthbook.com/articles/cardiovasculardisease_heartdisease.php

Lung Cancer: http://www.nethealthbook.com/articles/cancer_lungcancer.php

Last edited December 10, 2012